Clinical Trial Update: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Letetresgene Autoleucel alone and with pembrolizumab in NY-ESO-1 positive multiple myeloma; the study is terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Letetresgene Autoleucel (letetresgene autoleucel)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2022-01-11